Healthcare

Total revenues fell $18.0 million year over year. The decline was partly offset by a $31.4 million increase in contractManufacturingrevenue linked to commercial ELEVIDYSSupplydelivered to Roche, the collaboration partner in the product's commercialization. The mix of revenue sources within the quarter therefore differed from …

The specialty pharmacyBusinessgrew 44 percent, a faster rate than capitated revenue's 40 percent. Its 24 percent gross margin is the reference point for how much of each dollar of pharmacy revenue remains after cost of goods, which affects how the segment contributes to overall …

BLS Pharmaceuticals reported FY26 revenue of $74.2 million, up 161% from $29.3 million in FY25. The growth reflected the rapid scaling of the company's pharmaceutical manufacturing and distribution platform, including significant volumes supplied under international contracts. Adjusted EBITDA surged 171% to $19.0 million, achieving …

Star Combo Pharma reported FY25 group revenue of $27.8 million, up 6.9% from $26.0 million in FY24. The OEM Division — which provides contract manufacturing services to external clients — delivered external sales of $25.8 million (FY24: $23.3 million), with profit from operations of …

Biome Australia reported FY26 revenue of $23.9 million, up 30% from $18.4 million in FY25. This marks the company's strongest revenue year on record and continues a consistent growth trajectory, with the practitioner channel in Australia and New Zealand remaining the primary revenue driver. …

Wellnex Life's FY26 revenue of $24.8 million grew 5.1% from $23.6 million in FY25, which had itself grown 40.5% on FY24. The more significant FY26 story was profitability: EBITDA loss improved from approximately $12.1 million (FY25) to $1.7 million (FY26), a $10.4 million improvement. …

Elixinol Wellness's H1 FY26 revenue from continuing Australian operations was $7.2 million, up 5.8% from $6.8 million in H1 FY25. More significantly, gross margin improved from 33% (H1 FY25) to 43% (H1 FY26) — a 10 percentage point expansion driven by: exiting low-margin product …